Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design

Marco Valgimigli, Gianluca Campo, Nicoletta De Cesare, Pascal Vranckx, Martial Hamon, Dominick J. Angiolillo, Manel Sabatè, Fabrizio Ferrari, Alessandro Furgieri, Carlo Tumscitz, Alessandra Repetto, Salvatore Colangelo, Emanuele Meliga, Moh'd Kubbajeh, Giovanni Parrinello, Gianfranco Percoco, Roberto Ferrari

Research output: Contribution to journalArticle

Abstract

Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume22
Issue number4
DOIs
Publication statusPublished - Aug 2008

Fingerprint

tirofiban
clopidogrel
Aspirin
Percutaneous Coronary Intervention
Blood Platelets
Point-of-Care Systems
Myocardial Infarction
Troponin T
Platelet Glycoprotein GPIIb-IIIa Complex
Troponin I
Therapeutics
Sample Size
Outcome Assessment (Health Care)

Keywords

  • Aspirin resistance
  • Clopidogrel resistance
  • Platelet inhibition
  • Tirofiban

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. / Valgimigli, Marco; Campo, Gianluca; De Cesare, Nicoletta; Vranckx, Pascal; Hamon, Martial; Angiolillo, Dominick J.; Sabatè, Manel; Ferrari, Fabrizio; Furgieri, Alessandro; Tumscitz, Carlo; Repetto, Alessandra; Colangelo, Salvatore; Meliga, Emanuele; Kubbajeh, Moh'd; Parrinello, Giovanni; Percoco, Gianfranco; Ferrari, Roberto.

In: Cardiovascular Drugs and Therapy, Vol. 22, No. 4, 08.2008, p. 313-320.

Research output: Contribution to journalArticle

Valgimigli, M, Campo, G, De Cesare, N, Vranckx, P, Hamon, M, Angiolillo, DJ, Sabatè, M, Ferrari, F, Furgieri, A, Tumscitz, C, Repetto, A, Colangelo, S, Meliga, E, Kubbajeh, M, Parrinello, G, Percoco, G & Ferrari, R 2008, 'Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design', Cardiovascular Drugs and Therapy, vol. 22, no. 4, pp. 313-320. https://doi.org/10.1007/s10557-008-6121-z
Valgimigli, Marco ; Campo, Gianluca ; De Cesare, Nicoletta ; Vranckx, Pascal ; Hamon, Martial ; Angiolillo, Dominick J. ; Sabatè, Manel ; Ferrari, Fabrizio ; Furgieri, Alessandro ; Tumscitz, Carlo ; Repetto, Alessandra ; Colangelo, Salvatore ; Meliga, Emanuele ; Kubbajeh, Moh'd ; Parrinello, Giovanni ; Percoco, Gianfranco ; Ferrari, Roberto. / Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. In: Cardiovascular Drugs and Therapy. 2008 ; Vol. 22, No. 4. pp. 313-320.
@article{9929fc8cd87448428056cba11e93c376,
title = "Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design",
abstract = "Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.",
keywords = "Aspirin resistance, Clopidogrel resistance, Platelet inhibition, Tirofiban",
author = "Marco Valgimigli and Gianluca Campo and {De Cesare}, Nicoletta and Pascal Vranckx and Martial Hamon and Angiolillo, {Dominick J.} and Manel Sabat{\`e} and Fabrizio Ferrari and Alessandro Furgieri and Carlo Tumscitz and Alessandra Repetto and Salvatore Colangelo and Emanuele Meliga and Moh'd Kubbajeh and Giovanni Parrinello and Gianfranco Percoco and Roberto Ferrari",
year = "2008",
month = "8",
doi = "10.1007/s10557-008-6121-z",
language = "English",
volume = "22",
pages = "313--320",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design

AU - Valgimigli, Marco

AU - Campo, Gianluca

AU - De Cesare, Nicoletta

AU - Vranckx, Pascal

AU - Hamon, Martial

AU - Angiolillo, Dominick J.

AU - Sabatè, Manel

AU - Ferrari, Fabrizio

AU - Furgieri, Alessandro

AU - Tumscitz, Carlo

AU - Repetto, Alessandra

AU - Colangelo, Salvatore

AU - Meliga, Emanuele

AU - Kubbajeh, Moh'd

AU - Parrinello, Giovanni

AU - Percoco, Gianfranco

AU - Ferrari, Roberto

PY - 2008/8

Y1 - 2008/8

N2 - Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.

AB - Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.

KW - Aspirin resistance

KW - Clopidogrel resistance

KW - Platelet inhibition

KW - Tirofiban

UR - http://www.scopus.com/inward/record.url?scp=48349103357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349103357&partnerID=8YFLogxK

U2 - 10.1007/s10557-008-6121-z

DO - 10.1007/s10557-008-6121-z

M3 - Article

C2 - 18561010

AN - SCOPUS:48349103357

VL - 22

SP - 313

EP - 320

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 4

ER -